| Title |
Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial
|
|---|---|
| Published in |
Drug Design, Development and Therapy, July 2013
|
| DOI | 10.2147/dddt.s45575 |
| Pubmed ID | |
| Authors |
Benchalak Maneeton, Narong Maneeton, Manit Srisurapanont, Kaweesak Chittawatanarat |
| Abstract |
Atypical antipsychotic drugs may have low propensity to induce extrapyramidal side effects in delirious patients. This study aimed to compare the efficacy and tolerability between quetiapine and haloperidol in controlling delirious behavior. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 9% |
| United Kingdom | 1 | 9% |
| Unknown | 9 | 82% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Practitioners (doctors, other healthcare professionals) | 2 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Unknown | 140 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 12% |
| Other | 16 | 11% |
| Student > Master | 15 | 11% |
| Student > Bachelor | 14 | 10% |
| Professor > Associate Professor | 11 | 8% |
| Other | 37 | 26% |
| Unknown | 32 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 69 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 8% |
| Nursing and Health Professions | 7 | 5% |
| Psychology | 6 | 4% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 12 | 8% |
| Unknown | 33 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2020.
All research outputs
#3,075,086
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#166
of 2,268 outputs
Outputs of similar age
#25,341
of 206,711 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 39 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,711 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.